/ /

Cheryl Guttman Krader
Bone supportive therapy increases likelihood of pain palliation
Administering bone supportive therapy within 1 month prior to starting radium Ra 223 dichloride (Xofigo) may increase the likelihood of achieving pain palliation with the radionuclide therapy and reduce the chance of pain flare, according to the findings of a retrospective study.
PDE-5 inhibitors and melanoma: No causal link found
Findings of a meta-analysis show that phosphodiesterase type 5 inhibitor use is associated with a statistically significant increased risk of melanoma, but they do not support a causal relationship.
Hypothermia during RARP: No significant benefit seen
Although theory and preliminary clinical data indicated that intraoperative regional hypothermia could improve the return to potency and continence after robot-assisted radical prostatectomy, the intervention did not have any significant benefits when put to the more rigorous test of a randomized controlled trial.
Embolization for BPH shows long-term safety, efficacy
Findings of a retrospective study including 1,000 men with follow-up ranging to 8 years demonstrate the long-term safety and efficacy of prostatic artery embolization for relieving lower urinary tract symptoms secondary to BPH, researchers reported at the Society of Interventional Radiology annual scientific meeting in Washington.
RRP plus castration linked to improved survival
“We believe that aggressive loco-regional resection may be worth considering in well-selected patients as a part of a multimodal approach in the management of men with node-positive prostate cancer,” says study author Bimal Bhindi, MD.
Cryo most cost-effective fertility preservation strategy
Cryopreservation is far more cost-effective than post-treatment surgical sperm extraction and assisted reproductive technology for men with testis cancer who desire fertility preservation, new data show.
Urologists show low adherence to value-based care pathway
Urologists’ adherence to value-based care pathways for BPH surgery is extremely low and only modestly improved when given individualized feedback on patient outcomes, costs, and practice patterns relative to peers, say UCLA researchers.
Should RCC immunotherapy continue after progression?
Some patients being treated with nivolumab (Opdivo) for advanced renal cell carcinoma may still derive benefit if continued on the immunotherapy after disease progression, according to an analysis of phase III study data.
Urothelial Ca immunotherapy approved for first-line use
“Modern immunotherapy is active in advanced urothelial carcinoma and represents the most important advancement in the treatment of this disease in over 30 years,” says investigator Arjun V. Balar, MD.
Study: Consumer ads prompt men to seek TRT
Findings of an ecologic study indicate that direct-to-consumer advertising for testosterone therapy influenced men to seek treatment and was accompanied by increased testosterone prescribing, including initiation in men without clear indications for use.